Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News Archive
Showing 1811 results
January 2016
-
Media Release
Novartis receives two new FDA approvals for Cosentyx to treat patients with ankylosing spondylitis and psoriatic arthritis in the US
Cosentyx is the first and only interleukin-17A (IL-17A) inhibitor approved for adult patients with ankylosing spondylitis (AS) and psoriatic arthritis (PsA) FDA approval for Cosentyx is… -
Media Release
Novartis continues to grow immuno-oncology pipeline through collaboration and licensing agreement with Surface Oncology
Agreement gives Novartis access to four pre-clinical programs that target regulatory T cell populations, inhibitory cytokines, and immunosuppressive metabolites in the tumor microenvironment… -
Media Release
Novartis Pharmaceuticals collaborates with Qualcomm in digital innovation with the Breezhaler(TM) inhaler device to treat COPD
The Breezhaler(TM) inhaler is the device for Novartis' portfolio of COPD treatments of Onbrez and Seebri, and Ultibro, the leading LABA/LAMA treatment The collaboration further supports Novartis'… -
In The News
A new era of healthcare innovation
We are experiencing a new wave of innovation in health care – one that promises to create the smartest, most connected, and most efficient health systems the world has ever seen.
December 2015
-
Media Release
Novartis announces NEJM publication of two major trials showing significant efficacy of Cosentyx in ankylosing spondylitis patients
Cosentyx (secukinumab) is the first IL-17A inhibitor approved in Europe to treat ankylosing spondylitis (AS) and first treatment advance in 16 years since anti-tumor necrosis factor (anti-TNF)… -
Media Release
300 million child-friendly antimalarial treatments supplied without profit by Novartis
Coartem® Dispersible*, the first WHO prequalified[1] pediatric antimalarial treatment, has become the standard of care in over 30 malaria-endemic countries Since 2009, Novartis has supplied 300… -
Media Release
Sandoz advances its biosimilars program with European Medicines Agency (EMA) acceptance of regulatory submission for biosimilar etanercept
Sandoz is seeking approval for all indications included in the reference product's label which includes chronic inflammatory conditions like rheumatoid arthritis and psoriasis. Sandoz believes… -
Media Release
Novartis highlights new CTL019 Phase II data demonstrating 93% complete remission in pediatric patients with r/r ALL
55 of 59 patients experienced complete remissions in a single-arm study of the largest investigational CART therapy in children and young adults[1] Additional data presented include analyses on… -
Media Release
Phase III data shows Sandoz' proposed biosimilar pegfilgrastim has similar safety and efficacy as the reference product
PROTECT 2 study compared safety and efficacy of the proposed biosimilar pegfilgrastim with the reference product for the prevention of neutropenia in patients with breast cancer. The study met… -
Media Release
Novartis drug PKC412 (midostaurin) improves overall survival by 23% in global Phase III study of AML patients with FLT3 mutations
Study in partnership with the Alliance for Clinical Trials in Oncology is the first large controlled trial to show overall survival benefit in FLT3-mutated AML AML is the most common acute… -
Media Release
Novartis announces new CTL019 study data demonstrating overall response in adult patients with certain types of lymphoma
Overall response rate at 3 months was 47% (7/15) in diffuse large B-cell lymphoma and 73% (8/11) in follicular lymphoma Successful technology transfer enabling commercial scale-up of CTL019… -
Media Release
Novartis announces Phase III studies of Jakavi show disease improvement in patients with myelofibrosis and polycythemia vera
Data suggest myelofibrosis (MF) patients treated with Jakavi® (ruxolitinib) after 5 years lived longer despite crossover from best available therapy after week 48[1] Phase III results show…